XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Xynomic Pharmaceuticals Holdings, Inc. (Nasdaq: XYN) is a clinical-stage biopharmaceutical company focused on oncology therapeutics. The company became publicly traded through a SPAC business combination and filed its annual report on Form 10-K with the SEC on June 1, 2020, covering operations in the healthcare and pharmaceutical sector. At the time of filing, Xynomic was advancing a pipeline of cancer treatment candidates targeting both U.S. and international markets, including China, positioning itself as a cross-border oncology development platform. The accession number on record is 0001213900-20-013743. For full filing history, deal structure details, and real-time SPAC analytics on XYN and thousands of other companies, sign up for a free SpacDesk account at SpacDesk.com.